[Supports for the toxicity of the molecular target medicine].
Division of Breast Oncology, Saitama Cancer Center.
Kenichi
K
Inoue
D020533:Angiogenesis Inhibitors / Q000633:toxicity*; D061067:Antibodies, Monoclonal, Humanized / Q000633:toxicity*; D000970:Antineoplastic Agents / Q000633:toxicity*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000077341:Lapatinib; D058990:Molecular Targeted Therapy / Q000009:adverse effects*; D011799:Quinazolines / Q000633:toxicity*; D000068878:Trastuzumab
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D011799:Quinazolines; D000077341:Lapatinib; D000068258:Bevacizumab; D000068878:Trastuzumab